Sickle cell disease+1
RecruitingLong-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment
Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment
- Disease:Sickle cell diseaseThalassaemia
- Substances:Etavopivat
Greece- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Etavopivat
- Sponsor:Novo Nordisk A/S














